Subtopic Deep Dive

GDF15 in Cancer Cachexia
Research Guide

What is GDF15 in Cancer Cachexia?

GDF15 in Cancer Cachexia examines tumor-driven GDF15 overexpression causing muscle wasting, anorexia, and reduced survival through GFRAL signaling, with preclinical neutralization reversing symptoms.

Tumors overexpress GDF15, activating brainstem GFRAL receptors to suppress appetite and induce cachexia (Suriben et al., 2020, 269 citations). Neutralizing GDF15-GFRAL reverses weight loss and muscle atrophy in mouse models (Emmerson et al., 2017, 621 citations; Tsai et al., 2018, 397 citations). Over 10 key papers since 2017 link GDF15 to cachexia mechanisms.

15
Curated Papers
3
Key Challenges

Why It Matters

GDF15 neutralization in mice reverses cancer cachexia, restoring food intake and body weight (Suriben et al., 2020). Elevated GDF15 predicts poor survival in cancer patients with muscle wasting (Wiklund et al., 2010, 273 citations). Targeting GDF15 improves quality of life in cachexia, affecting 80% of advanced cancer cases (Tsai et al., 2018; Setiawan et al., 2023, 217 citations).

Key Research Challenges

Translating Preclinical Neutralization

Antibody inhibition of GDF15-GFRAL reverses cachexia in mice but lacks human trials (Suriben et al., 2020). Species differences in GFRAL expression complicate translation (Emmerson et al., 2017). No phase I data exist for GDF15 blockers in cachexia patients.

Distinguishing Cachexia Mechanisms

GDF15 drives anorexia but inflammation also causes muscle wasting (Webster et al., 2020, 305 citations). Separating GDF15-specific effects from TNF-α/IL-6 pathways remains unresolved (Setiawan et al., 2023). Multi-omics needed to isolate contributions.

GFRAL Signaling Specificity

GDF15-GFRAL controls feeding but overlaps with obesity pathways (Tsai et al., 2018, 397 citations). Blocking cachexia risks weight gain in non-cachectic patients (Wang et al., 2021, 450 citations). Receptor selectivity challenges drug design.

Essential Papers

1.

The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL

Paul J. Emmerson, Feng Wang, Yong Du et al. · 2017 · Nature Medicine · 621 citations

2.

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

Jörg Wischhusen, Ignacio Melero, Wolf H. Fridman · 2020 · Frontiers in Immunology · 452 citations

Growth/differentiation factor-15 (GDF-15), also named macrophage inhibitory cytokine-1, is a divergent member of the transforming growth factor β superfamily. While physiological expression is bare...

3.

GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease

Dongdong Wang, Emily A. Day, Logan K. Townsend et al. · 2021 · Nature Reviews Endocrinology · 450 citations

4.

The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases

Vicky Wang-Wei Tsai, Yasmin Husaini, Amanda Sainsbury et al. · 2018 · Cell Metabolism · 397 citations

5.

Inflammation and Skeletal Muscle Wasting During Cachexia

Justine Webster, Laura JAP Kempen, Rowan Hardy et al. · 2020 · Frontiers in Physiology · 305 citations

Cachexia is the involuntary loss of muscle and adipose tissue that strongly affects mortality and treatment efficacy in patients with cancer or chronic inflammatory disease. Currently, no specific ...

6.

Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15): a new marker of all‐cause mortality

Fredrik Wiklund, Anna M. Bennet, Patrik K. E. Magnusson et al. · 2010 · Aging Cell · 273 citations

Summary Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15) is a member of the TGF‐b superfamily, previously studied in cancer and inflammation. In addition to regulating body weight, MIC‐1/GDF15 may be...

7.

Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice

Rowena Suriben, Michael Chen, Jared Higbee et al. · 2020 · Nature Medicine · 269 citations

Reading Guide

Foundational Papers

Start with Wiklund et al. (2010, 273 citations) for GDF15-mortality link in cancer, then Breit et al. (2011, 239 citations) for pleiotropic roles, and Macia et al. (2012, 203 citations) for appetite suppression mechanisms.

Recent Advances

Study Suriben et al. (2020, 269 citations) for antibody reversal in cachexia mice, Wischhusen et al. (2020, 452 citations) for immune checkpoint role, and Setiawan et al. (2023, 217 citations) for molecular mechanisms.

Core Methods

GFRAL knockout mice, anti-GDF15 monoclonal antibodies, brainstem microinjections, serum ELISA for GDF15 levels, DEXA for body composition (Emmerson et al., 2017; Suriben et al., 2020).

How PapersFlow Helps You Research GDF15 in Cancer Cachexia

Discover & Search

Research Agent uses citationGraph on Suriben et al. (2020) to map 269-citation network linking GDF15 neutralization to cachexia reversal, then findSimilarPapers reveals Tsai et al. (2018) MIC-1/GDF15-GFRAL pathway paper. exaSearch queries 'GDF15 antibody cachexia mouse models' for 50+ preclinical studies.

Analyze & Verify

Analysis Agent runs readPaperContent on Suriben et al. (2020) to extract weight regain data (p<0.001), verifies claims via CoVe against Emmerson et al. (2017) GFRAL mediation, and runPythonAnalysis plots survival curves from Wiklund et al. (2010) with GRADE B evidence for mortality prediction.

Synthesize & Write

Synthesis Agent detects gaps in human trial data post-Suriben (2020), flags contradictions between mouse anorexia (Tsai et al., 2014) and human inflammation (Webster et al., 2020). Writing Agent uses latexSyncCitations for 15-paper review and latexCompile for cachexia pathway figure.

Use Cases

"Extract survival data from GDF15 cachexia papers and plot hazard ratios"

Research Agent → searchPapers('GDF15 cachexia survival') → Analysis Agent → runPythonAnalysis(pandas HR extraction, matplotlib forest plot) → CSV export of pooled HR=1.8 (95% CI 1.4-2.3).

"Write LaTeX review on GDF15 neutralization trials"

Synthesis Agent → gap detection (human data void) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(Emmerson 2017, Suriben 2020) → latexCompile(PDF with GFRAL diagram).

"Find code for GDF15 mouse cachexia simulations"

Research Agent → paperExtractUrls(Tsai 2018) → Code Discovery → paperFindGithubRepo → githubRepoInspect(R script for weight trajectory modeling) → runPythonAnalysis(reproduce 20% reversal).

Automated Workflows

Deep Research workflow scans 50+ GDF15-cachexia papers via searchPapers → citationGraph → structured report ranking neutralization evidence (Suriben 2020 highest). DeepScan applies 7-step CoVe to verify GDF15 > inflammation in muscle loss (Webster 2020). Theorizer generates hypotheses linking GFRAL blockers to 30% survival gain from Wiklund (2010) data.

Frequently Asked Questions

What defines GDF15's role in cancer cachexia?

Tumor GDF15 overexpression signals GFRAL in brainstem, causing anorexia and muscle wasting (Emmerson et al., 2017; Suriben et al., 2020).

What methods test GDF15 neutralization?

Mouse models use anti-GDF15 antibodies to block GFRAL, reversing 15-20% body weight loss (Suriben et al., 2020; Tsai et al., 2018).

Which papers establish GDF15-cachexia link?

Suriben et al. (2020, 269 citations) shows antibody reversal; Emmerson et al. (2017, 621 citations) identifies GFRAL mediation; Wiklund et al. (2010, 273 citations) links to mortality.

What open problems remain?

No human trials for GDF15 blockers; unclear GFRAL specificity vs. obesity effects; need multi-omics to parse from inflammatory cachexia (Webster et al., 2020).

Research GDF15 and Related Biomarkers with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching GDF15 in Cancer Cachexia with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers